Roche Holding Ltd.’s (ADR) (OTCMKTS:RHHBY) unit Genentech reports Phase 3 study for Gazyva shows superior progression-free survival compared to Rituxan-based standard of care treatment (RHHBY). The firm announced data from the positive, pivotal Phase III GALLIUM study that compared Gazyva plus chemotherapy followed by Gazyva alone head-to-head against Rituxan plus chemotherapy followed by Rituxan alone for people with previously untreated follicular lymphoma.
At a pre-planned interim analysis in May 2016, an independent data monitoring committee determined that the study met its primary endpoint early.The results showed Gazyva-based treatment reduced the risk of disease worsening or death (progression-free survival; PFS, as assessed by investigator) by 34 percent compared to Rituxan-based treatment.
Several matter pinch shares of Hilton Worldwide Holdings Inc. (NYSE:HLT) [Trend Analysis], as shares moving up 3.29% to $26.09 with a share volume of 18.43 Million. Hilton Worldwide Holdings (HLT) announced Monday that its Board of Directors has approved the spin-off of Park Hotels & Resorts Inc. and Hilton Grand Vacations Inc.The Board approved the distribution to its shareholders of all of the outstanding shares of Park Hotels & Resorts, which will become the holder of a portfolio of hotels and resorts previously held by Hilton, and Hilton Grand Vacations, Hilton’s timeshare business.
The spin-off transactions are expected to be completed on January 3, 2017, and Park and HGV will begin regular-way trading on the New York Stock Exchange under the ticker symbols “PK” and “HGV,” respectively, on January 4, 2017. The stock is going forward its 52-week low with 63.48% and moving down from its 52-week high price with 2.51%. To have technical analysis views, liquidity ratio of a company was calculated 1.20 as evaluated with its debt to equity ratio of 1.60. The float short ratio was 7.41%, as compared to sentiment indicator; Short Ratio was 4.93.